Login to Your Account

Avera's Venture Round Gets $48M For Neuroscience Bid

By Randall Osborne

Thursday, August 5, 2004
Although going about the typical process for a biotechnology firm backward, Avera Pharmaceuticals Inc. proved it can make the model work, raising $48 million in a Series C round of venture capital funding. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription